Evidence map›Paper›PMID 28343355›Full record

ArticlePediatric nephrology (Berlin, Germany)2017

Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus.

Cécile Picard, Jean-Christophe Lega, Bruno Ranchin, Pierre Cochat, Natalia Cabrera, Nicole Fabien, Alexandre Belot

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Does the esv3587290 Copy Number Variation in theChildren (Basel, Switzerland) · 2024
    Article
  4. Mendelian Causes of Autoimmunity: the Lupus Phenotype.Journal of clinical immunology · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Cécile PicardDepartment of Pathology, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, 59 boulevard Pinel, 69500, Bron, France. cecile.picard@chu-lyon.fr.ORCID 0000-0001-9284-4531
Jean-Christophe LegaUniversité Claude Bernard Lyon 1, Lyon, France.
Bruno RanchinUniversité Claude Bernard Lyon 1, Lyon, France.
Pierre CochatUniversité Claude Bernard Lyon 1, Lyon, France.
Natalia CabreraUniversité Claude Bernard Lyon 1, Lyon, France.
Nicole FabienUniversité Claude Bernard Lyon 1, Lyon, France.
Alexandre BelotUniversité Claude Bernard Lyon 1, Lyon, France.
Université Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildhood-onset systemic lupus erythematosus (cSLE) is rare, and considered more severe than its adult-onset counterpart. Lupus nephritis (LN) occurs more frequently in children, accounting for higher long-term morbidity and mortality compared with adults. Thus, reliable biological markers are needed to predict disease course. This study aimed to investigate the capacity of anti-C1q autoantibodies (Abs) to predict renal flare and global disease activity in cSLE patients, and association with disease activity and kidney involvement.

methodsTwenty-eight patients with cSLE including 19 patients (68%) with a history of LN were included retrospectively. Anti-C1q Abs were analysed by ELISA at renal flare-up or in the quiescent phase of disease and compared with Farr dsDNA assay.

resultsThirty-one flares occurred during follow-up: anti-C1q Abs were positive in 26 (84%), strongly associated with active disease status (p < 0.0001), and correlated with global disease activity score (p < 0.0001) and anti-dsDNA Abs presence (p < 0.0001). The specificity of anti-C1q Abs was higher than anti-dsDNA (73% vs 19%) in discriminating LN patients, whereas the receiver operating characteristic curves were not statistically different (0.83 ± 0.06 vs 0.78 ± 0.08 respectively), similar to C3 dosage. The presence of anti-C1q Abs at diagnosis was not predictive for global or renal flare. Introduction of a modified SLEDAI score excluding dsDNA Abs, demonstrated a stronger correlation of anti-C1q Abs titres with SLEDAI score in comparison with the Farr test.

conclusionAnti-C1q Abs seem very specific to flares, including LN in children, and their role in daily practice compared with the Farr dsDNA assay needs to be defined.

Indexed as

Symptom Flare UpAdolescentAge of OnsetAutoantibodiesBiomarkersChildChild, PreschoolComplement C1qDNAEnzyme-Linked Immunosorbent AssayFemaleHumansKidneyLupus NephritisMaleRetrospective StudiesAutoantibodiesBiomarkersComplement C1qDNAAnti-C1q antibodyBiomarkerChildhood-onset systemic lupus erythematosusLupus nephritisPediatricsSLEDAI

Identifiers

PMID28343355
OpenAlexW2597945585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.